Genetic Technologies, University of Melbourne collaborate on CRC risk assessment tool: 3 notes

Genetic Technologies and Australia-based University of Melbourne have entered a license agreement to develop a new colorectal cancer risk assessment test.

Here’s what you need to know:

1. The risk assessment tool stratifies patients into risk categories based on susceptibility to single-nucleotide polymorphisms.

2. A goal of the risk assessment tool is to identify people at high and low risk for colorectal cancer, to assist patients when deciding what age and frequency they should begin screening.

3. Genetic Technologies, a molecular diagnostics company, is responsible for the commercial development of the test. The company has already developed a risk assessment test for sporadic breast cancer, called BREVAGenplus, which uses a similar technology.

4. University of Melbourne will leverage its expertise in single-nucleotide polymorphism and DNA sequencing to partner with Genetic Technologies in ongoing research related to this risk assessment tool.

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers

Featured Podcast